Hsu C D, Copel J A, Hong S F, Chan D W
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut, USA.
Obstet Gynecol. 1995 Dec;86(6):897-9. doi: 10.1016/0029-7844(95)00326-M.
To measure the circulating levels of thrombomodulin in women with preeclampsia, gestational hypertension, and chronic hypertension.
Serum levels of thrombomodulin were measured in 34 women with preeclampsia, 15 with gestational hypertension, 11 with chronic hypertension, and 34 normotensive pregnant women in the third trimester. Preeclampsia, gestational hypertension, and chronic hypertension were defined by ACOG criteria. Soluble thrombomodulin antigen was measured by a two-site enzyme-linked immunosorbent assay.
Mean (+/- standard error) serum thrombomodulin levels were significantly higher in patients with preeclampsia (69.7 +/- 6.3 ng/mL) than in those with gestational hypertension (46.0 +/- 3.2 ng/mL) or chronic hypertension (46.2 +/- 3.3 ng/mL), and normotensive controls (50.1 +/- 3.1 ng/mL). There were no significant differences among the gestational hypertension, chronic hypertension, and normotensive control groups.
Thrombomodulin may serve as a clinically meaningful marker to differentiate preeclampsia from other forms of hypertensive disorders in pregnancy.
测定子痫前期、妊娠期高血压和慢性高血压女性患者循环中血栓调节蛋白的水平。
测定34例子痫前期女性、15例妊娠期高血压女性、11例慢性高血压女性以及34例孕晚期血压正常的孕妇血清中血栓调节蛋白的水平。子痫前期、妊娠期高血压和慢性高血压均根据美国妇产科医师学会（ACOG）标准进行定义。采用双位点酶联免疫吸附测定法检测可溶性血栓调节蛋白抗原。
子痫前期患者血清血栓调节蛋白平均水平（69.7±6.3 ng/mL）显著高于妊娠期高血压患者（46.0±3.2 ng/mL）、慢性高血压患者（46.2±3.3 ng/mL）以及血压正常对照组（50.1±3.1 ng/mL）。妊娠期高血压组、慢性高血压组和血压正常对照组之间无显著差异。
血栓调节蛋白可能是一种具有临床意义的标志物，用于区分子痫前期与其他妊娠高血压疾病。
